PriceTargets.com logo

Nektar Therapeutics - NKTR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $3.50
  • Forecasted Upside: 250.00%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.00 As of 11/20/2024 01:00 AM ET
▼ -0.03 (-2.91%)

This chart shows the closing price for NKTR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nektar Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NKTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NKTR

Analyst Price Target is $3.50
▲ +250.00% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $3.50, with a high forecast of $7.00 and a low forecast of $1.00. The average price target represents a 250.00% upside from the last price of $1.00.

This chart shows the closing price for NKTR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in Nektar Therapeutics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/4/2024Piper SandlerInitiated CoverageOverweight$7.00
9/30/2024BTIG ResearchReiterated RatingBuy$4.00
6/28/2024Rodman & RenshawInitiated CoverageBuy$2.00
3/6/2024Jefferies Financial GroupBoost TargetHold ➝ Hold$0.50 ➝ $1.00
3/5/2024William BlairReiterated RatingMarket Perform
11/20/2023JPMorgan Chase & Co.Reiterated RatingUnderweight
11/9/2023TD CowenUpgradeMarket Perform ➝ Outperform
8/7/2023MizuhoReiterated RatingNeutral$6.00
5/10/2023Jefferies Financial GroupUpgradeUnderperform ➝ Hold$1.50 ➝ $1.00
3/6/2023OppenheimerLower TargetMarket Perform$5.00 ➝ $3.00
2/27/2023The Goldman Sachs GroupLower TargetSell$3.00 ➝ $2.00
2/24/2023SVB SecuritiesLower Target$5.00 ➝ $3.00
2/24/2023Leerink PartnersLower TargetMarket Perform$5.00 ➝ $3.00
2/24/2023Jefferies Financial GroupDowngradeHold ➝ Underperform$3.20 ➝ $1.50
8/8/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
4/20/2022OppenheimerDowngradeOutperform ➝ Market Perform
4/18/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell$3.00
4/18/2022Leerink PartnersLower TargetMarket Perform$7.00 ➝ $6.00
4/18/2022MizuhoLower TargetNeutral$8.00 ➝ $6.00
3/16/2022Canaccord Genuity GroupLower TargetBuy$25.00 ➝ $6.00
3/15/2022Leerink PartnersLower TargetMarket Perform$18.00 ➝ $7.00
3/15/2022MizuhoDowngradeBuy ➝ Neutral$35.00 ➝ $8.00
3/14/2022CowenDowngradeOutperform ➝ Market Perform$35.00 ➝ $8.00
3/14/2022OppenheimerDowngradeOutperform ➝ Market Perform
3/14/2022Stifel NicolausDowngradeBuy ➝ Hold$24.00 ➝ $5.00
3/14/2022BTIG ResearchDowngradeBuy ➝ Neutral
3/14/2022William BlairDowngradeOutperform ➝ Market Perform
3/14/2022Bank of AmericaDowngradeNeutral ➝ Underperform$18.00 ➝ $6.00
3/9/2022OppenheimerUpgradeMarket Perform ➝ Outperform$21.00
3/1/2022JPMorgan Chase & Co.Lower Target$24.00 ➝ $17.00
11/8/2021BTIG ResearchLower TargetPositive ➝ Buy$80.00 ➝ $54.00
11/8/2021Leerink PartnersLower TargetMarket Perform$19.00 ➝ $18.00
11/8/2021BenchmarkUpgradeHold ➝ Buy$20.00
11/5/2021OppenheimerLower TargetMarket Perform$25.00 ➝ $21.00
9/10/2021Bank of AmericaInitiated CoverageNeutral$18.00
8/6/2021Leerink PartnersLower TargetMarket Perform$20.00 ➝ $19.00
6/28/2021Stifel NicolausUpgradeHold ➝ Buy$22.00 ➝ $24.00
5/10/2021Leerink PartnersLower TargetMarket Perform$21.00 ➝ $20.00
5/7/2021MizuhoReiterated RatingBuy
4/6/2021Leerink PartnersBoost TargetMarket Perform$20.00 ➝ $21.00
3/1/2021BenchmarkReiterated RatingBuy ➝ Hold$26.00
2/22/2021BenchmarkDowngradeBuy ➝ Hold$26.00
1/5/2021Stifel NicolausInitiated CoverageHold$18.00
11/12/2020Leerink PartnersBoost TargetMarket Perform$17.00 ➝ $20.00
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutral$26.00
8/14/2020Leerink PartnersLower TargetMarket Perform$18.00 ➝ $17.00
8/7/2020OppenheimerReiterated RatingHold$25.00
6/10/2020CfraDowngradeHold ➝ Sell
5/26/2020MizuhoInitiated CoverageBuy$35.00
5/18/2020OppenheimerBoost TargetMarket Perform$24.00 ➝ $25.00
5/12/2020HC WainwrightLower TargetNeutral$32.00 ➝ $26.00
5/8/2020Leerink PartnersBoost TargetMarket Perform$17.00 ➝ $18.00
4/22/2020BenchmarkInitiated CoverageBuy$26.00
4/2/2020MizuhoReiterated RatingBuy$35.00
3/30/2020The Goldman Sachs GroupUpgradeSell ➝ Neutral$18.00 ➝ $20.00
3/9/2020JPMorgan Chase & Co.Lower TargetNeutral$28.00 ➝ $27.00
3/4/2020BarclaysInitiated CoverageOverweight$30.00
2/28/2020Piper SandlerReiterated RatingBuy$35.00
2/28/2020BTIG ResearchLower TargetBuy$101.00 ➝ $80.00
2/28/2020William BlairReiterated RatingOutperform
2/28/2020CowenReiterated RatingBuy$27.00
2/12/2020CowenReiterated RatingBuy$30.00
2/3/2020MizuhoReiterated RatingNeutral ➝ Buy$21.00 ➝ $35.00
1/10/2020MizuhoInitiated CoverageHold$21.00
1/10/2020HC WainwrightReiterated RatingHold$32.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 6 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 7 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 3 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 3 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Nektar Therapeutics logo
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $1.00
Low: $1.00
High: $1.07

50 Day Range

MA: $1.28
Low: $1.00
High: $1.45

52 Week Range

Now: $1.00
Low: $0.42
High: $1.93

Volume

1,485,696 shs

Average Volume

1,798,017 shs

Market Capitalization

$184.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Nektar Therapeutics?

The following sell-side analysts have issued stock ratings on Nektar Therapeutics in the last year: BTIG Research, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Rodman & Renshaw, StockNews.com, and William Blair.
View the latest analyst ratings for NKTR.

What is the current price target for Nektar Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Nektar Therapeutics in the last year. Their average twelve-month price target is $3.50, suggesting a possible upside of 250.0%. Piper Sandler has the highest price target set, predicting NKTR will reach $7.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $1.00 for Nektar Therapeutics in the next year.
View the latest price targets for NKTR.

What is the current consensus analyst rating for Nektar Therapeutics?

Nektar Therapeutics currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NKTR.

What other companies compete with Nektar Therapeutics?

Other companies that are similar to Nektar Therapeutics include ADC Therapeutics, Seres Therapeutics, Atea Pharmaceuticals, Omeros and Assembly Biosciences. Learn More about companies similar to Nektar Therapeutics.

How do I contact Nektar Therapeutics' investor relations team?

Nektar Therapeutics' physical mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company's listed phone number is (415) 482-5300 and its investor relations email address is [email protected]. The official website for Nektar Therapeutics is www.nektar.com. Learn More about contacing Nektar Therapeutics investor relations.